Journal of Clinical Gynecology and Obstetrics, ISSN 1927-1271 print, 1927-128X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Gynecol Obstet and Elmer Press Inc
Journal website http://www.jcgo.org

Original Article

Volume 3, Number 3, September 2014, pages 85-92

Does Lower Uterine Segment Involvement in Grade 3 Endometrial Cancer Impact Recurrence Patterns and Patient Outcomes?

Figures

Figure 1.
Figure 1. Progression free survival by LUS.
Figure 2.
Figure 2. Overall survival by LUS.

Tables

Table 1. Demographic Data for Lower Uterine Segment Positive and Negative Tumors
 
LUS-positive (n = 137) (% or SD)LUS-negative (n = 145) (% or SD)P value
Age (mean)65.5 (10.9)66.8 (10.8)0.3267
Race0.099
Caucasian81 (59.1)100 (69.0)
African American49 (35.8)35 (24.1)
Other7 (5.1)10 (6.9)
BMI (mean)32.5 (8.3)31.1 (8.2)0.1905
Overweight-obese108 (78.8)109 (75.2)0.527
Diabetes34 (24.8)33 (22.8)0.685
Hypertension78 (57.8)86 (59.7)0.742
Adjuvant therapy106 (77.4)90 (62.1)0.005
Radiation90 (65.7)73 (50.3)0.021
Chemotherapy83 (60.6)68 (46.9)0.066
Recurrence53 (38.7)30 (20.7)0.001

 

Table 2. Stage and Uterine Characteristics Associated With Lower Uterine Segment Positive and Negative Tumors
 
LUS-positive (%)LUS-negative (%)P value
aLypmhovascular invasion.
Primary stage< 0.001
I67 (48.9)121 (83.5)
II20 (14.6)3 (2.1)
III50 (36.5)21 (14.5)
Histology0.148
Endometrioid42 (30.7)60 (41.4)
Serous/clear cell68 (49.6)64 (44.1)
Carcinosarcoma27 (19.7)21 (14.5)
LVSIa72 (52.9)43 (30.5)< 0.001
Myometrial invasion > 50%67 (48.9)35 (24.1)< 0.001
Nodal metastases46 (38.7)15 (11.6)< 0.001
Pelvic node +42 (37.2)14 (11.2)
Para-aortic node +23 (23.5)7 (6.0)

 

Table 3. Location of Recurrence in Lower Uterine Segment Positive and Negative Tumors
 
LUS-positive (%)LUS-negative (%)P value
Vaginal recurrence12 (22.6)6 (20.0)0.223
Pelvic recurrence5 (9.4)7 (23.3)
Extrapelvic recurrence36 (67.9)17 (56.7)